PharmaEngine : The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders' Meeting (Additional cause for convening the meeting)
The Company's Board of Directors resolved to
convene the 2022 Annual General Shareholders' Meeting
(Additional cause for convening the meeting)
Date of events
2022/03/08
To which item it meets
paragraph 17
Statement
1.Date of the board of directors resolution:2022/03/08
2.General shareholders' meeting date:2022/05/27
3.General shareholders' meeting location:
B2F., No. 8, Sec. 3, Minsheng E. Rd., Zhongshan Dist., Taipei City
104511 , Taiwan (R.O.C.) (Amazing Hall, Minsheng Branch)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):Physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:
A. 2021 business report and 2022 business plan
B. Audit Committee's review of the 2021 annual final accounting ledgers
and statements
C. Report on 2021 employees' and directors' remuneration
D. The amendments of 2013 cash capital increasing plan
E. To report the execution status of buying back treasury shares in 2021
and the Amendments of treasury shares transferred to employees
regulations
6.Cause for convening the meeting II.Acknowledged matters:
A. Acknowledgment of the 2021 annual final accounting ledgers and
statements.
B. Acknowledgment of the 2021 Earnings Distribution.
7.Cause for convening the meeting III.Matters for Discussion:
A. Discussion of the amendments to the Operating Procedures of Fund Lending
B. Discussion of amendments to the Company's "Procedures for Asset
Acquisition & Disposal"
C. Discussion of amendments to the Company's "Procedures for Election
of Directors"
D. Discussion of amendments to the Company's "Articles of Incorporation"
E. Discussion of Issuance of restricted stock awards
8.Cause for convening the meeting IV.Election matters:
Election of new directors
9.Cause for convening the meeting V.Other Proposals:
the lifting of non-competition restrictions for new-elected directors and
representatives of the company
10.Cause for convening the meeting VI.Extemporary Motions:None
11.Book closure starting date:2022/03/29
12.Book closure ending date:2022/05/27
13.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 08 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 March 2022 10:30:07 UTC.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
PharmaEngine : The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders' Meeting (Additional cause for convening the meeting)
PHARMAENGINE, INC. 
